Eurobio Oncology

EndoPredict^®: Understanding your Test Results

Regardless of Your Result, Treatment is Personalized to You

Your EndoPredict test result is more than just a number – it’s a powerful tool to guide your treatment decisions together with your doctor.

What are the EPclin Risk Score and Risk Class?

You will receive a number called the EPclin Risk Score. It combines the activity of certain genes in your tumor with clinical factors like tumor size and lymph node status. This score, shown on a scale from 1 to 6, helps estimate your individual risk of breast cancer coming back – and places you into a personal risk class.

EndoPredict shows your personal risk of breast cancer returning within the next 10 years if you receive 5 years of hormone therapy alone.¹ It also helps estimate how much additional benefit chemotherapy might offer to you.² Since recurrence can still happen after chemotherapy, the test supports you and your doctor in weighing its potential benefit against possible side effects.

This information will help you and your doctor to make an informed decision about your initial treatment.

"EndoPredict provided information about my risk profile, helping me better understand my situation and discuss treatment options with my care team."

Our Patient Feedback

EndoPredict shows your individual risk of breast cancer returning in the 10 years after completing 5 years of hormone therapy.³ This helps you and your doctor decide whether 5 years of treatment might be enough or if extended hormone therapy may be needed.

You receive this information before starting any medication – so you can make the right treatment choices for now and for the future.

"Knowing from the beginning that I would only need to take hormone therapy for five years gave me the confidence to stay on it - even when the side effects were hard. Having a clear end in mind made all the difference.“

Our Patient Feedback

Want to Learn More at Your Own Pace?

References

Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019